NCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
BeOne Medicines
BeOne Medicines
iOMEDICO AG